Continue to meet or exceed healthcare partners’ expectations by providing on-time test results approximately 92 percent of the time.
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...